Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020

January 24, 2021 updated by: Iwona Gorczyca, Jan Kochanowski University

Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) over therapy with vitamin K antagonists (VKA) in most AF patients. The number of patients treated with NOACs has increased significantly during the last few years. In the primary randomized controlled trials leading to their approval, compared to warfarin, NOACs were shown to be either noninferior or superior for stroke prevention in AF, with similar or reduced rates of bleeding, especially intracranial haemorrhage.

The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with AF.

Study Overview

Status

Unknown

Conditions

Atrial Fibrillation; Stroke Prevention

Intervention / Treatment

Other: observational study

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Poland
- - Kielce, Poland, 25-525
    - Recruiting
    - Iwona Gorczyca
    - Contact:
      
      Iwona Gorczyca, MD,PhD
      
      Phone Number: +48 604 40 79 56
      
      Email: iwona.gorczyca@interia.pl
    - Contact:
      
      Olga Jelonek, MD
      
      Email: olga_jelonek@wp.pl
- Grunwaldzka 45
  - Kielce, Grunwaldzka 45, Poland, 25-637
    - Recruiting
    - 1st Clinic of Cardiology and Electotherapy
    - Contact:
      
      Iwona Gorczyca, MD, PhD
      
      Phone Number: +48 604407956
      
      Email: iwona.gorczyca@interia.pl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with AF treated in hospital.

Description

Inclusion Criteria:

- non-valvular atrial fibrillation

Exclusion Criteria:

valvular atrial fibrillation
death during hospitalization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
oral anticoagulant treatment Time Frame: one year	one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jan Kochanowski University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Anticipated)

March 1, 2021

Study Completion (Anticipated)

May 1, 2021

Study Registration Dates

First Submitted

December 22, 2020

First Submitted That Met QC Criteria

December 22, 2020

First Posted (Actual)

December 28, 2020

Study Record Updates

Last Update Posted (Actual)

January 26, 2021

Last Update Submitted That Met QC Criteria

January 24, 2021

Last Verified